A vaccine for the world’s most common cause of acute gastroenteritis and the USA’s most common cause of foodborne illness is now in human clinical trials. The trial by Japan’s Takeda Pharmaceutical Co. Ltd. involves the first norovirus vaccine prospect to enter human adult or efficacy trials. Rob Goodwin, vice
Continue Reading Takeda’s norovirus vaccine first to reach human trials
Public Library of Science (PLOS)
Worldwide human and economic costs of norovirus are huge
By News Desk on
Leave it to the federal Centers for Disease Control and Prevention to put a price tag on the worldwide cost of norovirus. After a CDC-sponsored symposium in February, scientists and experts calculated the global numbers, estimating 200,000 deaths and an economic cost of $60 billion annually. The Public Library of…
Continue Reading Worldwide human and economic costs of norovirus are huge